IGKV3OR22-2

Across TCGA pan-cancer cohorts, IGKV3OR22-2 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of IGKV3OR22-2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where IGKV3OR22-2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types IGKV3OR22-2 is over-expressed in tumor, although a few such as BRCA and LIHC show the opposite, repressed pattern.

LUAD, BRCA, and LIHC are the cancer types where IGKV3OR22-2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGKV3OR22-2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	All	+0.479	<.001	7	view →
BRCA	Female	All	−0.086	.008	4	view →
LIHC	All	II,III,IV	−0.044	.024	2	view →
COAD	All	IV	−0.770	.028	1	view →
STAD	Male	All	−0.482	.046	1	view →
READ	All	All	−0.436	.022	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

IGKV3OR22-2–LUAD

Open the LUAD breakdown →